Bacteria-derived vesicles and uses thereof
Non-naturally occurring vesicles derived from bacteria, e.g., pathogenic bacteria, methods for making the vesicles, and methods for using compositions of these vesicles are disclosed. Methods of using the vesicles include prevention and/or treatment of bacterial infections. Also provided herein are compositions that include vesicles derived front bacteria and tumor vesicles, methods for making the tumor vesicles, and methods for using the compositions of bacterial vesicles and tumor vesicles. Methods of using the compositions of bacterial vesicles and tumor vesicles include treatment of cancer in a subject. Tumor vesicles may be derived from cancer cells present in the subject to be treated or from a cancer cell line expressing at least one neoantigen. The neoantigen may be specific to the subject and may have been identified by sequencing of the cancer cells from the subject. The neoantigen may be a neoantigen known to be commonly expressed in a particular type of cancer.
1. A composition comprising non-naturally occurring artificial outer membrane vesicles (aOMVs) generated from a gram-negative bacterium,
wherein the aOMVs are deficient in the following components present in the gram-negative bacterium: periplasmic proteins, inner membrane proteins, nucleic acids, cytoplasmic proteins, and ribosomes; and
wherein the aOMVs are enriched in outer membrane proteins,
wherein the gram-negative bacterium is not genetically modified to reduce production of lipopolysaccharides (LPS), and
wherein when administered to a subject, the aOMVs produce a reduced inflammatory response comprising production of a lower level of tumor necrosis factor alpha (TNF-α) and/or interleukin-6 (IL-6), as compared to that produced by administering naturally occurring outer membrane vesicles (OMVs) released by the gram-negative bacterium.
2. The composition of claim 1 , further comprising tumor vesicles (TVs), wherein the TVs comprise at least one tumor antigen.
3. The composition of claim 1 , wherein the aOMVs are loaded with a therapeutic agent.
4. The composition of claim 1 , wherein the aOMVs are loaded with a STING agonist, wherein the aOMVs loaded with the STING agonist form a layer between 30% and 50% iodixanol when ultracentrifuged on a density gradient formed by 10%, 30%, and 50% iodixanol.
5. The composition of claim 4 , wherein the STING agonist is a cyclic dinucleotide (CDN) or 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
6. A method for producing an immune response to a gram-negative bacterium in a mammalian subject, the method comprising administering the composition of claim 1 to the subject in an amount effective to induce an immune response to the gram-negative bacterium in the mammalian subject.
7. The method of claim 6 , wherein the administering produces reduced inflammatory response comprising production of a lower level of tumor necrosis factor alpha (TNF-α) and/or interleukin-6 (IL-6), as compared to that produced by administering naturally occurring OMVs released by the gram-negative bacterium.
8. A method for treating cancer in a subject, the method comprising administering to the subject the composition of claim 2 .
9. The method of claim 8 , wherein the administering results in induction of antibodies against the tumor vesicles at a titer more than twice the titer of antibodies against the tumor vesicles induced using an adjuvant instead of the aOMVs.
10. The method of claim 8 , further comprising administering an immune checkpoint inhibitor to the subject.
11. The method of claim 10 , wherein the immune checkpoint inhibitor comprises an anti-PD-1 antibody or an anti-PDL1 antibody.
12. The method of claim 11 , wherein the administration of aOMVs, TVs, and the anti-PD-1 antibody results in reduction of tumor volume in the subject which reduction is at least two times higher than achieved by administration of aOMVs and the anti-PD-1 antibody or TVs and the anti-PD-1 antibody.
13. The method of claim 8 , wherein the aOMVs are prepared by revesiculation of vesicles composed of outer membrane.
14. The method of claim 13 , wherein revesiculation comprises exposing the vesicles to an alkaline pH.
15. The method of claim 8 , wherein the administering comprises intratumoral injection.
16. A method for generating non-naturally occurring artificial outer membrane vesicles (aOMVs) from a gram-negative bacterium, the method comprising:
a) disrupting a spheroplast generated from the gram-negative bacterium to generate vesicles comprising outer membrane and vesicles comprising inner membrane, optionally wherein disrupting comprises applying shear force to the spheroplast or acoustic energy to the spheroplast;
b) exposing the vesicles to an ionic surfactant to disrupt vesicles comprising inner membrane and to an alkaline pH to open the vesicles comprising outer membrane thereby generating outer membrane sheets;
c) purifying the outer membrane sheets; and
d) applying energy to the purified outer membrane sheets sufficient to convert the outer membrane sheets into aOMVs, thereby generating the-non-naturally occurring aOMVs.
17. The method of claim 16 , comprising generating the spheroplast from the gram-negative bacterium by incubating the gram-negative bacterium with lysozyme under conditions sufficient for the removal of the peptidoglycan layer in cell wall of the gram-negative bacterium, thereby converting the gram-negative bacterium into the spheroplast.
18. The method of claim 16 , wherein step b) comprises exposing the vesicles to the ionic surfactant to disrupt vesicles comprising inner membrane, isolating the vesicles comprising the outer membrane, and exposing the vesicles comprising the outer membrane to the alkaline pH.
19. The method of claim 18 , wherein the alkaline pH comprises a pH of 11-14.
20. A method for generating non-naturally occurring artificial outer membrane vesicles (aOMVs) from a gram-negative bacterium, the method comprising:
a) disrupting a spheroplast generated from the gram-negative bacterium to generate vesicles comprising outer membrane and vesicles comprising inner membrane, optionally wherein disrupting comprises applying shear force to the spheroplast or acoustic energy to the spheroplast;
b) exposing the vesicles to an ionic surfactant to disrupt vesicles comprising inner membrane and to an alkaline pH to open the vesicles comprising outer membrane thereby generating outer membrane sheets;
c) purifying the outer membrane sheets; and
d) in the presence of a STING agonist, applying energy to the purified outer membrane sheets sufficient to convert the outer membrane sheets into aOMVs, thereby generating the non-naturally occurring aOMVs comprising the STING agonist.